Abstract:BACKGROUND:Diabetes is associated with an increased risk of cardiac microvascular disease. The mechanisms by which this damage occurs are unknown. However, research suggests that signaling through the sphingosine-1-phosphates receptor 1 and 3 (S1P1/3) by FTY720, a sphiongolipid drug that is structually similar to SIP, may play a role in the treatment on cardiac microvascular dysfunction in diabetes. We hypothesized that FTY720 might exert the cardioprotective effects of S1P1 and S1P3 viaprotein kinase C-beta (PKCβ II) signaling pathway.METHODOLOGY/PRINCIPAL FINDINGS:Transthoracic echocardiography was performed to detect the change of cardiac function. Scanning and transmission electron microscope with lanthanum tracer were used to determine microvascular ultrastructure and permeability in vivo. Apoptosis was detected by TUNEL and CD31 dual labeling in paraffin-embedded sections. Laser capture miscrodissection was used to assess cardiac micovascular endothelial cells (CMECs) in vivo. RT-PCR and Western blot analysis were used to determine the mRNA levels and protein expression of S1P1, S1P3, and PKCβ II. In the diabetic rats vs. controls, cardiac capillaries showed significantly higher density; CD31 positive endothelial cells were significantly reduced; the apoptosis index of cardiac endothlial cells was significantly higher. And FTY720 could increase the expressional level of S1P1 and boost S1P3 trasnslocation from membrane to nuclear, then ameliorate cardiac microvascular barrier impairment and pathologic angiogenesis induced by diabetes. In addition, overexpression of PKCβ II significantly decreased the protective effect of FTY720.CONCLUSIONS:Our study represents that the deregulation of S1P1 and S1P3 is an important signalresponsible for cardiac microvascular dysfunction in diabetes. FTY720 might be competent to serve as a potential therapeutic approach for diabetic heart disease through ameliorating cardiac microvascular barrier impairment and pathologic angiogenesis, which might be partly dependent on PKCβII-mediated signaling pathway.

Expression of Farnesyl Pyrophosphate Synthase is Increased in Diabetic Cardiomyopathy.

Cardiac-specific Overexpression of Farnesyl Pyrophosphate Synthase Induces Cardiac Hypertrophy and Dysfunction in Mice.

Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy.

Inhibition of farnesyl pyrophosphate synthase attenuates angiotensin II-induced cardiac hypertrophy and fibrosis in vivo.

Cardiac‐specific Deletion of FDPS Induces Cardiac Remodeling and Dysfunction by Enhancing the Activity of Small GTP‐binding Proteins

Inhibition of Farnesyl Pyrophosphate Synthase Improves Pressure Overload Induced Chronic Cardiac Remodeling

Chronic inhibition of farnesyl pyrophosphate synthase attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats.

Knock-down of Farnesyl Pyrophosphate Synthase Protects Heart-Derived H9c2 Cells Against Hypoxia/reoxygenation-Induced Injury.

Expression Changes Of Mitogen-Actilvated Protelin Kinase Phosphatase-1 (Mkp-1) In Myocardium Of Streptozotocin-Induced Diabetic Rats

Expression changes of thrombospondin-1 and neuropeptide Y in myocardium of STZ-induced rats.

Overexpression of Farnesyl Pyrophosphate Synthase Increases Myocardial Ischemia/reperfusion Injury in Mice.

Single-cell Analysis Reveals Lysyl Oxidase (lox)+ Fibroblast Subset Involved in Cardiac Fibrosis of Diabetic Mice.

Establishment of transgenic mice carrying the gene for farnesyl pyrophosphate synthase

Inhibition of Farnesyl Pyrophosphate Synthase Prevents Angiotensin II-induced Cardiac Fibrosis in Vitro.

GW24-e2384 the Role of Farnesyl Pyrophosphate Synthase in Angiotensin II-induced Cardiac Fibrosis

Knock-down of Farnesyl Pyrophosphate Synthase Protects Heart-derived H 9 c 2 Cells Against Hypoxia / Reoxygenation-Induced Injury † Running title Effect of FPPS on HR Injury in H 9 c 2 Cells

FP-receptor Gene Silencing Ameliorates Myocardial Fibrosis and Protects from Diabetic Cardiomyopathy.

GW24-e2448 Knockdown of Farnesyl Pyrophosphate Synthase Prevents Cardiac Fibrosis of Spontaneously Hypertensive Ratsin Vivo

Diabetes Promotes Myocardial Fibrosis via AMPK/EZH2/PPAR-γ Signaling Pathway

Inhibition of farnesyl pyrophosphate synthase alleviates cardiomyopathy in diabetic rat

Fty720 Protects Cardiac Microvessels of Diabetes: A Critical Role of S1p1/3 in Diabetic Heart Disease